Login to Your Account

GPC Draws $10M Up Front In Japanese Marketing Deal

By Randall Osborne

Tuesday, June 26, 2007
One month away from an FDA panel review, GPC Biotech Inc.'s satraplatin for prostate cancer has become the subject of a $10 million license deal with Yakult Honsha Co. Ltd., for rights in Japan. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription